TY - JOUR
T1 - A randomized Phase III trial of lobe-specific vs. systematic nodal dissection for clinical Stage I-II non-small cell lung cancer (JCOG1413)
AU - on behalf of the Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group (JCOG-LCSSG)
AU - Hishida, Tomoyuki
AU - Saji, Hisashi
AU - Watanabe, Shun Ichi
AU - Asamura, Hisao
AU - Aokage, Keiju
AU - Mizutani, Tomonori
AU - Wakabayashi, Masashi
AU - Shibata, Taro
AU - Okada, Morihito
N1 - Funding Information:
This work is supported in part by a Grant-in-Aid for Cancer Research (26-A-4) from the Ministry of Health, Labour and Welfare of Japan.
Publisher Copyright:
© The Author(s) 2017. Published by Oxford University Press.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - In January 2017, the Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group commenced a randomized Phase III trial to confirm the clinical benefit of lobe-specific nodal dissection for clinical Stage I-II non-small cell lung cancer. The primary endpoint is overall survival, and the main objective is to confirm the non-inferiority of lobe-specific in comparison to systematic nodal dissection with regard to lobectomy. The secondary endpoints are relapse-free survival, %local recurrence, %regional lymph node recurrence, operation time, blood loss, length of hospitalization, duration of chest tube placement and adverse events. A total of 1700 patients will be accrued from 44 Japanese institutions within 5 years. This study is the first and large prospective trial to evaluate whether the difference in the area of nodal dissection affects the overall survival of patients with relatively early-stage non-small cell lung cancer. This trial has been registered in the UMIN Clinical Trials Registry as UMIN000025530.
AB - In January 2017, the Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group commenced a randomized Phase III trial to confirm the clinical benefit of lobe-specific nodal dissection for clinical Stage I-II non-small cell lung cancer. The primary endpoint is overall survival, and the main objective is to confirm the non-inferiority of lobe-specific in comparison to systematic nodal dissection with regard to lobectomy. The secondary endpoints are relapse-free survival, %local recurrence, %regional lymph node recurrence, operation time, blood loss, length of hospitalization, duration of chest tube placement and adverse events. A total of 1700 patients will be accrued from 44 Japanese institutions within 5 years. This study is the first and large prospective trial to evaluate whether the difference in the area of nodal dissection affects the overall survival of patients with relatively early-stage non-small cell lung cancer. This trial has been registered in the UMIN Clinical Trials Registry as UMIN000025530.
KW - Lobe-specific
KW - Lymph node dissection
KW - Non-small-cell lung cancer
KW - Randomized Phase III study
KW - Systematic
UR - http://www.scopus.com/inward/record.url?scp=85042913073&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042913073&partnerID=8YFLogxK
U2 - 10.1093/jjco/hyx170
DO - 10.1093/jjco/hyx170
M3 - Article
C2 - 29177507
AN - SCOPUS:85042913073
SN - 0368-2811
VL - 48
SP - 190
EP - 194
JO - Japanese Journal of Clinical Oncology
JF - Japanese Journal of Clinical Oncology
IS - 2
ER -
